Physician profile
Harendra K Punatar
NPI 1699773432
$4,950.84
in general payments reported to CMS, 2019-2025
27 companies · $35.96 in 2025
The $35.96 reported for 2025 was less than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,049 · 2020: $1,050 · 2021: $954 · 2022: $1,077 · 2023: $755 · 2024: $29.98 · 2025: $35.96.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $821.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $821.15 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $517.84 | 2019-2022 | |
| Novartis Pharmaceuticals Corporation | $479.88 | 2019-2023 | |
| Medtronic, INC. | $452.21 | 2021-2023 | Micra |
| Amgen INC. | $438.21 | 2019-2023 | Repatha |
| Kowa Pharmaceuticals America, INC. | $375.99 | 2019-2022 | |
| Edwards Lifesciences Corporation | $276.55 | 2020-2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $275.87 | 2019-2023 | Jardiance |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $258.15 | 2019-2023 | Lifevest |
| Janssen Pharmaceuticals, INC | $239.57 | 2019-2022 | |
| E.R. Squibb & Sons, L.L.C. | $209.69 | 2019-2023 | Eliquis |
| Esperion Therapeutics, INC. | $199.26 | 2020-2023 | Nexletol |
| Amarin Pharma, INC. | $186.28 | 2020-2021 | |
| Boston Scientific Corporation | $165.08 | 2021-2024 | Watchman Access System, Bodyguardian |
| Bardy Diagnostics, INC. | $152.93 | 2020-2021 | |
| Astrazeneca Pharmaceuticals Lp | $132.11 | 2019-2021 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $114.82 | 2019-2021 | |
| Baxter Healthcare | $90.21 | 2022 | |
| Sanofi-Aventis U.S. LLC | $81.10 | 2019 | |
| Actelion Pharmaceuticals US, INC. | $57.76 | 2019-2023 | Opsumit, Uptravi |
| Irhythm Technologies, INC. | $53.83 | 2019-2022 | |
| Octapharma USA, INC. | $35.96 | 2025 | Fibryga |
| Regeneron Healthcare Solutions, INC. | $35.84 | 2019 | |
| Kiniksa Pharmaceuticals, Ltd. | $30.17 | 2022 | |
| Medtronic Vascular, INC. | $25.65 | 2019 | |
| Merck Sharp & Dohme LLC | $24.98 | 2021 | |
| Gilead Sciences, INC. | $23.18 | 2019 | |
| Preventice Services, LLC | $17.72 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Harendra Punatar listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.